Century Therapeutics appoints Morgan Conn, Ph.D. as CFO effective Oct 14, 2024

Century Therapeutics, Inc.

Morgan Conn, formerly CBO of Pharvaris, appointed CFO; effective October 14, 2024.
Annual base salary of $470,000; target bonus of 40% of base; $100,000 signing bonus.
Equity award: option to purchase 360,890 shares and RSU covering 60,148 shares.
Option vests 25% on first anniversary, remainder monthly over 3 years; RSU vests 25% first year, quarterly thereafter.
Severance includes 9 months salary and COBRA, extended to 12 months upon change in control.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Morgan Conn

Chief Financial Officer

IPSC · Century Therapeutics, Inc.

Effective: 2024-10-14
Filed: September 26, 2024, 7:59 PM ET

On September 26, 2024, the Century Therapeutics, Inc. (the “Company”) announced the appointment of Morgan Conn, Ph.D. to serve as the Company’s Chief Financial Officer, effective October 14, 2024 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Morgan Conn was appointed as Chief Financial Officer at Century Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On September 26, 2024, the Century Therapeutics, Inc. (the “Company”) announced the appointment of Morgan Conn, Ph.D. to serve as the Company’s Chief Financial Officer, effective October 14, 2024 (the “Effective Date”).

View on SEC.gov

Century Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-102988

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.